The goal of our preclinical studies for cancer treatment are currently focused on preclinical evaluation of combination therapy with two drugs, rapamycin (mTOR inhibitor) and MS-275 (HDAC, histone deactylase inhibitor) which interact with the two signal transduction pathways, RB and PI3K. These drugs have been evaluated in tissue culture cell lines for the following cancers: multiple myeloma, plasmacytoma or plasma cell tumors, and mantle cell lymphoma.Combined treatment with low concentrations of MS-275 and rapamycin resulted in a synergistic effect on growth inhibition in vitro and in vivo. Rapamycin decreased phosphorylation of S6, and MS-275 increased acetylation of histone H3 and H4. Both effects were further accentuated by the combination treatment. Both drugs caused cell cycle arrest, via different signaling events;MS-275 induced the expression of p21, p27 and p16, whereas rapamycin reduced the expression of cyclin D and p21. In contrast to rapamycin alone, the combination treatment did not lead to MAPK or AKT activation. MS-275 and rapamycin increased, and their combination further enhanced, the expression of pro-apoptotic proteins Foxo and Bim, and decreased expression of the pro-survival protein Survivin. The therapeutic potential of the combination was supported by in vivo studies of MM xenografts.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Calabrese, David R; Zlotkowski, Katherine; Alden, Stephanie et al. (2018) Characterization of clinically used oral antiseptics as quadruplex-binding ligands. Nucleic Acids Res 46:2722-2732
Calabrese, David R; Chen, Xiang; Leon, Elena C et al. (2018) Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex. Nat Commun 9:4229
He, Yunlong; Zhu, Wentao; Shin, Min Hwa et al. (2017) cFOS-SOX9 Axis Reprograms Bone Marrow-Derived Mesenchymal Stem Cells into Chondroblastic Osteosarcoma. Stem Cell Reports 8:1630-1644
Simmons, John K; Michalowski, Aleksandra M; Gamache, Benjamin J et al. (2017) Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation. Mol Cancer Ther 16:2008-2021
Felsenstein, Kenneth M; Saunders, Lindsey B; Simmons, John K et al. (2016) Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression. ACS Chem Biol 11:139-48
Eiden, Adrian M; Zhang, Shuling; Gary, Joy M et al. (2016) Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy. Clin Cancer Res 22:277-83
Simmons, John K; Patel, Jyoti; Michalowski, Aleksandra et al. (2014) TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Mol Oncol 8:261-72
Simmons, John K; Amlin-Van Schaick, Jessica C; Geiger, Thomas R et al. (2012) Mouse genetics 2011: meeting report. Mamm Genome 23:225-31
Smrz, Daniel; Kim, Mi-Sun; Zhang, Shuling et al. (2011) mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood 118:6803-13
Zhang, Shuling; Readinger, Julie A; DuBois, Wendy et al. (2011) Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood 117:1228-38